Related references
Note: Only part of the references are listed.Prolactin-regulated Pbk is involved in pregnancy-induced β-cell proliferation in mice
Yan Cao et al.
JOURNAL OF ENDOCRINOLOGY (2022)
PBK expression predicts favorable survival in colorectal cancer patients
Aya Nagano-Matsuo et al.
VIRCHOWS ARCHIV (2021)
Menin-regulated Pbk controls high fat diet-induced compensatory beta cell proliferation
Jian Ma et al.
EMBO MOLECULAR MEDICINE (2021)
PDZ Binding Kinase/T-LAK Cell-Derived Protein Kinase Plays an Oncogenic Role and Promotes Immune Escape in Human Tumors
Tingting Feng et al.
JOURNAL OF ONCOLOGY (2021)
PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential
Hai Huang et al.
CANCERS (2021)
Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms
Lena Weindl et al.
ENDOCRINE-RELATED CANCER (2021)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y
M. Pavel et al.
ANNALS OF ONCOLOGY (2020)
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Oliver Klein et al.
CLINICAL CANCER RESEARCH (2020)
mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
Sara Zanini et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer
Anne Y. Warren et al.
ONCOGENE (2019)
Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis
Tiantao Gao et al.
CANCER LETTERS (2019)
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth
Shaikamjad Umesalma et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances
Amr Mohamed et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma
Tingting Feng et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma
Hanlin Ma et al.
CELL DEATH & DISEASE (2019)
PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway
Qiu-Xia Yang et al.
CANCER LETTERS (2019)
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial
Guy Jerusalem et al.
JAMA ONCOLOGY (2018)
Enhanced Expression of the Key Mitosis Regulator Cyclin B1 Is Mediated by PDZ-Binding Kinase in Islets of Pregnant Mice
Tadayoshi Uesato et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma
Takuma Ohashi et al.
BRITISH JOURNAL OF CANCER (2017)
Whole-genome landscape of pancreatic neuroendocrine tumours
Aldo Scarpa et al.
NATURE (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
P. Christopoulos et al.
ANNALS OF ONCOLOGY (2017)
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
R. J. Motzer et al.
ANNALS OF ONCOLOGY (2016)
Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma
Takuma Ohashi et al.
ANTICANCER RESEARCH (2016)
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
Timon Vandamme et al.
BRITISH JOURNAL OF CANCER (2016)
Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Adriana Soler et al.
CLINICAL CANCER RESEARCH (2016)
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors
Simona Falletta et al.
ENDOCRINE-RELATED CANCER (2016)
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Characterization of PDZ-binding kinase, a mitotic kinase
S Gaudet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
